Status: Recruiting
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
Participants needed: 12
Trial details
Phase: Phase 4Age: 12+Biological sex: AllType: InterventionalSponsor: Amryt PharmaUpdated: Jul 3, 2025Locations: 12
Eligibility criteria
Confirmed diagnosis of familial or acquired partial lipodystrophy
Treatment with any Investigational Medicinal Product (IMP) within 6 months or 5...